|
Name |
Talaromycin B
|
| Molecular Formula | C12H22O4 | |
| IUPAC Name* |
(3S,4S,6R,9R)-9-ethyl-3-(hydroxymethyl)-1,7-dioxaspiro[5.5]undecan-4-ol
|
|
| SMILES |
CC[C@@H]1CC[C@@]2(C[C@@H]([C@H](CO2)CO)O)OC1
|
|
| InChI |
InChI=1S/C12H22O4/c1-2-9-3-4-12(15-7-9)5-11(14)10(6-13)8-16-12/h9-11,13-14H,2-8H2,1H3/t9-,10+,11+,12-/m1/s1
|
|
| InChIKey |
VDWRKBZMQNPUOB-NOOOWODRSA-N
|
|
| Synonyms |
Talaromycin B; (-)-Talaromycin B; 83780-27-2; BE3756MH6J; 1,7-Dioxaspiro(5.5)undecane-3-methanol, 9-ethyl-4-hydroxy-, (3S,4S,6R,9R)-; (3S,4S,6R,9R)-9-ETHYL-3-(HYDROXYMETHYL)-1,7-DIOXASPIRO[5.5]UNDECAN-4-OL; TALAROMYCIN-B; UNII-BE3756MH6J; SCHEMBL10566018; DTXSID90232636; (3R,6R,8S,9S)-3-ETHYL-9-(HYDROXYMETHYL)-5,11-DIOXASPIRO(5.5)UNDECAN-8-OL; (3S,4S,6R,9R)-9-ETHYL-4-HYDROXY-1,7-DIOXASPIRO(5.5)UNDECANE-3-METHANOL; 1,7-DIOXASPIRO(5.5)UNDECANE-3-METHANOL, 9-ETHYL-4-HYDROXY-, (3S-(3.ALPHA.,4.BETA.,6.ALPHA.(S*)))-(3S,4S,6R,9R)-9-ETHYL-4-HYDROXY-1,7-DIOXASPIRO(5.5)UNDECANE-3-METHANOL
|
|
| CAS | 83780-27-2 | |
| PubChem CID | 158569 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 230.3 | ALogp: | 1.2 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 58.9 | Aromatic Rings: | 2 |
| Heavy Atoms: | 16 | QED Weighted: | 0.751 |
| Caco-2 Permeability: | -4.676 | MDCK Permeability: | 0.00004910 |
| Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.665 |
| Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.148 |
| 30% Bioavailability (F30%): | 0.006 |
| Blood-Brain-Barrier Penetration (BBB): | 0.333 | Plasma Protein Binding (PPB): | 23.54% |
| Volume Distribution (VD): | 1.591 | Fu: | 64.31% |
| CYP1A2-inhibitor: | 0.019 | CYP1A2-substrate: | 0.763 |
| CYP2C19-inhibitor: | 0.023 | CYP2C19-substrate: | 0.809 |
| CYP2C9-inhibitor: | 0.011 | CYP2C9-substrate: | 0.073 |
| CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.198 |
| CYP3A4-inhibitor: | 0.017 | CYP3A4-substrate: | 0.318 |
| Clearance (CL): | 11.509 | Half-life (T1/2): | 0.71 |
| hERG Blockers: | 0.097 | Human Hepatotoxicity (H-HT): | 0.286 |
| Drug-inuced Liver Injury (DILI): | 0.048 | AMES Toxicity: | 0.153 |
| Rat Oral Acute Toxicity: | 0.015 | Maximum Recommended Daily Dose: | 0.469 |
| Skin Sensitization: | 0.948 | Carcinogencity: | 0.815 |
| Eye Corrosion: | 0.857 | Eye Irritation: | 0.988 |
| Respiratory Toxicity: | 0.355 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000927 | ![]() |
1.000 | D04VIS | ![]() |
0.215 | ||
| ENC004715 | ![]() |
0.574 | D0HR8Z | ![]() |
0.197 | ||
| ENC002228 | ![]() |
0.250 | D0KR5B | ![]() |
0.196 | ||
| ENC004001 | ![]() |
0.250 | D0D1SG | ![]() |
0.196 | ||
| ENC004545 | ![]() |
0.234 | D0I1LH | ![]() |
0.194 | ||
| ENC005832 | ![]() |
0.229 | D0Z4EI | ![]() |
0.194 | ||
| ENC005945 | ![]() |
0.228 | D04QNO | ![]() |
0.191 | ||
| ENC003798 | ![]() |
0.225 | D0Y7IU | ![]() |
0.191 | ||
| ENC003906 | ![]() |
0.224 | D00ZTD | ![]() |
0.190 | ||
| ENC002918 | ![]() |
0.224 | D0U3CR | ![]() |
0.185 | ||